Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
A pharmacoeconomic analysis of the registration trials: Peginterferon alfa-2a plus ribvarin versus peginterferon alfa-2b plus ribavarin for treatment of genotype 1 chronic hepatitis C 56th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases Kamal, A., Lim, J. K., Crockett, S., Ahmed, A. WILEY-BLACKWELL. 2005: 352A–352A
View details for Web of Science ID 000232480300391